[12] Patent
[11] Patent No.:GC0007538  
[45] Date of Publishing the Grant of the Patent: 30/Apr /2018                48/2018  
Number of the Decision to Grant the Patent:2018/125778
Date of the Decision to Grant the Patent:08/Apr/2018

[21] Application No.:GC 2012-22126

[22] Filing Date:29/8/2012

[30] Priority:

[33] State [32] Priority date [31] Priority No.
US
US
8/9/2011
26/4/2012
61/532,459
61/638,588

[72] Inventors:1- Ann Taylor،2- Lloyd B. Klickstein

[73] Owner: Novartis AG, Lichtstrasse 35, Basel, Switzerland

[74] Agent: Saud M. A. Shawwaf Law Office

  

 

  

[51]IPC:
Int. Cl.: A61K 31/4196, 9/48 (2006.01)

[56] Cited Documents:

-SH ETTY GU NA PALA ET AL: “ Effect of estrogen deprivation on the reproductive physiology of male and female primates “, JOURNAL OF STEROID B !OCH EM I STRY AND MOLECULAR BIOLOGY,
vol. 61, no. 3-6, April 1997
-WO 03/082254 Al (JENCAP RES LTD [CA]; CASPER ROBERT F [CA]) 9 October 2003
-SH ETTY G ET AL: “ Effect of long-term treatment with aromatase inhibitor on testicular function of adult male bonnet monkeys (M. radiata) - Comparative study among different species of mammals “,
STEROIDS, ELSEVIER SCIENCE PUBLISHERS, NEW YORK, NY, US,
vol. 63, no. 7-8, 8 July 1998
-EP 0 490 816 A2 (CIBA GEIGY AG [CH]) 17 June 1992
-H. DE BOER ET AL: “ Letrozole normalizes serum testosterone in severely obese men with hypogonadotropic hypogonadism “,
DIABETES, OBESITY AND METABOLISM, vol. 7, no. 3, 1 May 2005
-LANG M ET AL: “ Structure-activity relationships and binding model of novel aromatase inhibitors “, JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, ELSEVIER SCIENCE LTD.,
OXFORD, GB, vol. 44, no. 4-6, 1 March 1993
 
Examiner: PH. Nada M. AlBehaiji

[54] USE OF AN AROMATASE INHIBITOR FOR THE TREATMENT OF HYPOGONADISM AND RELATED DISEASES
[57] Abstract: This invention relates to a method of increasing testosterone levels and treating hypogonadism and related diseases with the aromatase inhibitor 4,4'-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile. The present invention further relates to a method of increasing testosterone levels and treating hypogonadism and related diseases with the aromatase inhibitor 4,4'-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile in a particular dosing regimen. The invention also relates to pharmaceutical compositions comprising said aromatase inhibitor 4,4'-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile, optionally in combination with other active ingredients. Furthermore, the present invention relates to kits comprising said pharmaceutical compositions together with instructions how to administer them.
No. of claims: 9


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.